Georgia Bio Summer Interns look back on experience gained

This summer, Georgia Bio welcomed three ambitious and enthusiastic interns: Isabel Veith, Rob Warren, and Maanav Karamchandani. Our interns took some time to reflect on their internships and told us about their diverse career interests—education, politics, nonprofits—and how their internships influenced their career aspirations.

Isabel Veith, Senior Biology Major at Georgia Tech

Photo of Isabel Veith

Isabel was excited to learn about the inner workings of a nonprofit. “One of the reasons I was interested in this internship was learning the administrative and marketing side of a nonprofit. I have seen how making strategic connections between people and fostering relationships can benefit a cause.” 

During her internship, Isabel gained insight into life science education. “I learned how critical education is to the industry and how inconsistent life science opportunities and resources are in some schools. Middle and high school education is the foundation for the workforce, and I never thought about how a lack of opportunities and resources at those ages could have reverberating effects on the industry. I am very passionate about giving back to future generations. I am a firm believer in leaving a place better than you found it. I would like to eventually become a professor and be able to serve in a mentor capacity to students. I think you can make major impacts in a field just by providing encouraging words and guidance to young scientists.” 

Whatever her career path, Isabel now knows the importance of connection and working together to achieve a goal. “I would like to end up working in a nonprofit, but I think with any job I take, Georgia Bio has shown me that the way you approach a job or mission is crucial. Building networks and promoting collaboration can make all the difference.”

Rob Warren, Junior International Politics Major at Washington and Lee University

Rob says he gained great knowledge of the life sciences industry during his internship at Georgia Bio. “I had the opportunity to attend the Strategic Planning meeting in June, where I learned about the future of the industry, like drug price transparency. Attending events like this allowed me to learn more about the industry overall.” 

“I got to experience the policy and advocacy side of a trade organization. I helped with various projects, including researching policy to promote that aligns with the interests of our member organizations. I also had the opportunity to work on member engagement.” 

Rob says his time at Georgia Bio introduced him to a new potential career path. “Before the internship, I had no certain direction for my career. Now, I know I want to pursue business, maybe even lobbying. Working on policy opened me up to the business/politics career possibility.” 

Outside of science, Rob has a passion for travel. “I like to travel internationally; I’m studying abroad in Prague this fall. Some of the countries I’ve visited include Argentina, Chile, Italy, France, Canada, Mexico, Belize, and Switzerland. Exploring different cultures and places is very interesting, and I try to use what I learn from my travels in my everyday life.”

Maanav Karamchandani, Junior at Lambert High School

Maanav learned how he might one day break into the life sciences industry. “Before working with Georgia Bio, I had little exposure to the life sciences industry and was not very clear as to how I would get into the field. This internship provided me with countless opportunities to meet people working in the life sciences industry as well as learn how they got there. Georgia Bio made me a part of the team and allowed me to grow.”

He feels he really made an impact during his time at Georgia Bio. “The projects I did were a part of larger ones, and the impact of my work was visible immediately. Some of the projects I worked on include the Global Health ATL social media posts, the new Georgia Bio website, and providing new ways to increase member engagement.”

Manaav’s path to achieving his career goals was clarified thanks to his time at Georgia Bio. “I now know the type of education needed for my future career. I also have a better idea as to how to reach my goals and aspirations in this field. Meeting different people in the field has also allowed me to expand my mindset and see that there are many paths to reach my ambitions.” 

Outside of his studies, Manaav has already been making an impact on the world. “I am very passionate about community service. I founded my own nonprofit, www.myjal.org, at the age of seven to provide clean drinking water to people in need across the world.” MyJal has helped provide over 300 children and adults in need clean drinking water and continues to work on new projects. “MyJal is something that I am extremely proud of.”


All three of these interns show great passion when it comes to their career goals, and it sounds like they learned a great deal during their internships at Georgia Bio! We feel lucky to have spent the summer with these students and can’t wait to see what they accomplish in the future. Georgia Bio looks forward to welcoming more interns throughout the year and next summer!

By Maria Thacker Goethe October 22, 2025
“Evolving FTC and DOJ policies leave investors and innovators navigating a cautious M&A landscape
October 6, 2025
Atlanta, GA — October 6 — Georgia Life Sciences today announced the launch of Vitals, a new podcast series developed in partnership with Cloudcast Media, a leader in branded podcast production. The series will spotlight the people, ideas, and innovations shaping the future of Georgia’s rapidly growing life sciences sector. Hosted by Georgia Life Sciences’ CEO, Maria Thacker Goethe, Vitals will feature in-depth conversations with scientists, entrepreneurs, investors, educators, policymakers, and patient advocates. Each episode will explore the challenges and opportunities facing Georgia’s life sciences ecosystem—spanning biopharma, medical technology, digital health, and advanced manufacturing. “Vitals gives us a powerful platform to showcase the remarkable work happening within our state,” said Maria Thacker Goethe. “By sharing these stories, we’re highlighting not only groundbreaking science but also the collaboration and talent that make Georgia such a vibrant hub for health innovation.” Cloudcast Media, known for its expertise in storytelling and high-quality podcast production, will bring industry insights and technical support to ensure the series reaches audiences across Georgia and beyond. “We’re proud to partner with Georgia Life Sciences on Vitals,” said Charles Parisi, Founder and CEO of Cloudcast. “This series will elevate the voices of innovators who are advancing science, improving patient outcomes, and building Georgia’s reputation as a global life sciences leader. We are very excited that Cloudcast Atlanta can play a role in supporting Maria and the impactful work of Georgia Life Sciences.” The first episode of Vitals launched today and is available on Apple Podcasts, Spotify, and other major streaming platforms, as well as through the Georgia Life Sciences website.
October 1, 2025
September 30, 2025 WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on Most Favored Nation policies: "For too many years, Americans have subsidized the research and development necessary to bring newer and better medicines to patients around the world. As we saw with defense spending and NATO, the solution is not to weaken a strategically important American industry, but for other countries to pay their fair share. “Today’s announcement in the Oval Office highlights the problems with a drug delivery system where half of the cost of innovative medicines goes to middlemen and distributors, and where the supply chain distorts prices paid by the American people. We support a new framework that addresses the cost of medicines by simplifying the system - and making medicines directly available to patients. “But importing socialist price controls through most-favored nation policies fundamentally does not address the imbalance in international pricing for innovative medicines. MFN will not lower the out-of-pocket prices that most Americans pay for medicines. Even worse, it will jeopardize the entrepreneurial spirit and deter the capital necessary for a vibrant and essential American biotechnology industry to thrive and may cause most harm to small and midsize biotech companies, which are responsible for discovering more than half of all new treatments. “Without these biotech innovators and a free-market system, we risk slower scientific progress, decreased access to new medicines, compromised national security, fewer American jobs and perhaps most tragically, a diminished hope for those suffering with illness and disease. There are much better ways to address this problem than MFN.” ###
MORE POSTS